Fintel reports that on August 15, 2023, Benchmark reiterated coverage of Humacyte (NASDAQ:HUMA) with a Buy recommendation.
Analyst Price Forecast Suggests 79.89% Upside
As of August 2, 2023, the average one-year price target for Humacyte is 7.27. The forecasts range from a low of 2.78 to a high of $16.80. The average price target represents an increase of 79.89% from its latest reported closing price of 4.04.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Humacyte is 1MM, an increase of 4,445.16%. The projected annual non-GAAP EPS is -0.99.
What is the Fund Sentiment?
There are 160 funds or institutions reporting positions in Humacyte. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to HUMA is 0.05%, an increase of 52.26%. Total shares owned by institutions increased in the last three months by 4.19% to 13,101K shares. 
The put/call ratio of HUMA is 0.17, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,621K shares representing 1.57% ownership of the company. In it's prior filing, the firm reported owning 1,480K shares, representing an increase of 8.67%. The firm increased its portfolio allocation in HUMA by 48.06% over the last quarter.
IWM - iShares Russell 2000 ETF holds 1,189K shares representing 1.15% ownership of the company. In it's prior filing, the firm reported owning 1,151K shares, representing an increase of 3.22%. The firm increased its portfolio allocation in HUMA by 58.10% over the last quarter.
Geode Capital Management holds 1,054K shares representing 1.02% ownership of the company. In it's prior filing, the firm reported owning 875K shares, representing an increase of 16.96%. The firm increased its portfolio allocation in HUMA by 63.24% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 770K shares representing 0.74% ownership of the company. No change in the last quarter.
Prescott General Partners holds 568K shares representing 0.55% ownership of the company. No change in the last quarter.
Humacyte Background Information
(This description is provided by the company.)
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Additional reading:
- Press release, dated
- Revenue Interest Purchase Agreement, dated as of May 12, 2023, by and among Humacyte Global, Inc., Humacyte, Inc. and Hook SA LLC.
- Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair -Top-line results planned to be released in third quarter 2023 -Trial results are intended to support Biologics License Application (BLA) pl
- Option Agreement, dated as of May 12, 2023, by and among Humacyte, Inc., TPC Investments III LP and TPC Investments Solutions LP.
- Humacyte First Quarter 2023 Financial Results and Business Update - Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stag
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
